Table 2.
The differences of clinicoradiological characteristics in between training and testing datasets.
| Group | taining | testing | P-value |
|---|---|---|---|
| N | 402 | 99 | |
| Age (years) | 51.66 ± 10.89 | 52.93 ± 11.03 | 0.301 |
| PLT, 10^9/L | 156.62 ± 77.43 | 143.45 ± 62.58 | 0.117 |
| ALT, IU/L | 59.16 ± 87.60 | 85.86 ± 119.67 | 0.012 |
| AST, IU/L | 55.04 ± 73.86 | 80.45 ± 107.22 | 0.006 |
| ALB, g/L | 41.96 ± 5.11 | 41.48 ± 6.26 | 0.422 |
| TBIL, μmol | 17.42 ± 8.33 | 21.64 ± 32.26 | 0.020 |
| ALP, IU/L | 112.84 ± 91.99 | 112.46 ± 41.64 | 0.969 |
| APTT, sec | 27.61 ± 14.69 | 24.60 ± 10.11 | 0.054 |
| PT, sec | 13.17 ± 10.65 | 11.75 ± 1.17 | 0.186 |
| INR | 1.00 ± 0.09 | 1.04 ± 0.14 | <0.001 |
| Gender | 0.146 | ||
| 0, male | 348 (86.57%) | 80 (80.81%) | |
| 1, female | 54 (13.43%) | 19 (19.19%) | |
| AFP | 0.761 | ||
| 0, normal | 153 (38.93%) | 39 (40.62%) | |
| 1, abnormal | 240 (61.07%) | 57 (59.38%) | |
| Hbs Ag | 0.912 | ||
| 0, Hbs Ag(-) | 51 (12.85%) | 13 (13.27%) | |
| 1, Hbs Ag(+) | 346 (87.15%) | 85 (86.73%) | |
| Child-Pugh | 0.414 | ||
| 0, A | 394 (98.25%) | 96 (96.97%) | |
| 1, B | 7 (1.75%) | 3 (3.03%) | |
| Cirrhosis | 0.611 | ||
| 0, no | 107 (26.75%) | 29 (29.29%) | |
| 1,yes | 293 (73.25%) | 70 (70.71%) | |
| No. of nodes | 0.254 | ||
| 0, 1 | 373 (92.79%) | 95 (95.96%) | |
| 1, ≥ 2 | 29 (7.21%) | 4 (4.04%) | |
| The maximum length | 0.739 | ||
| 0,≤5cm | 275 (68.41%) | 66 (66.67%) | |
| 1, >5cm | 127 (31.59%) | 33 (33.33%) | |
| Shape | 0.179 | ||
| 0, circle | 161 (40.05%) | 47 (47.47%) | |
| 1, irregular | 241 (59.95%) | 52 (52.53%) | |
| Satellite nodules | 0.048 | ||
| 0, absent | 365 (91.02%) | 96 (96.97%) | |
| 1, present | 36 (8.98%) | 3 (3.03%) | |
| Capsule | 0.496 | ||
| 0, absence or incomplete | 194 (48.26%) | 44 (44.44%) | |
| 1, complete | 208 (51.74%) | 55 (55.56%) | |
| Intratumoral hemorrhage | 0.137 | ||
| 0, absent | 252 (62.69%) | 54 (54.55%) | |
| 1, present | 150 (37.31%) | 45 (45.45%) | |
| Intratumoral fat | 0.796 | ||
| 0, absent | 341 (84.83%) | 85 (85.86%) | |
| 1, present | 61 (15.17%) | 14 (14.14%) | |
| Arterial peritumoral enhancement | 0.294 | ||
| 0, absent | 301 (74.88%) | 69 (69.70%) | |
| 1, present | 101 (25.12%) | 30 (30.30%) | |
| Peritumoral hypotensity on HBP | 0.034 | ||
| 0, absent | 313 (77.86%) | 67 (67.68%) | |
| 1, present | 89 (22.14%) | 32 (32.32%) | |
| MVI grade | 0.993 | ||
| 0 | 202 (50.25%) | 50 (50.51%) | |
| 1 | 166 (41.29%) | 41 (41.41%) | |
| 2 | 34 (8.46%) | 8 (8.08%) |
MVI, microvascular invasion; M0: no MVI detected; M1 (low-risk group): 0<the number of MVI ≤ 5 and MVI occurred in the proximal paracancerous liver; M2 (high-risk group): the number of MVI > 5 MVI or MVI occurred in the distal paracancerous liver tissue area (> 1 cm). PLT, platelet count; ALT, alanine transarninase; AST, aspertate aminotransferase; ALB, serum albumin; TBIL, serum total bilirubin; ALP, alkaline phosphatase; APTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; AFP, serum afetoprotein; Hbs Ag, hepatitis B surface antigen; HBP, hepatobiliary phase